G Yancey Gillespie

List of Publications by Year
in descending order

139	9,587	36303	39675
papers	citations	51 h-index	94 g-index

140	140	140	11345
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clinical Cancer Research, 2022, 28, 498-506.	7.0	12
2	Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics, 2021, 11, 665-683.	10.0	89
3	N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. Journal of Clinical Investigation, 2021, 131, .	8.2	43
4	Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. New England Journal of Medicine, 2021, 384, 1613-1622.	27.0	173
5	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
6	SON drives oncogenic RNA splicing in glioblastoma by regulating PTBP1/PTBP2 switching and RBFOX2 activity. Nature Communications, 2021, 12, 5551.	12.8	17
7	Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. Cancer Gene Therapy, 2020, 27, 246-255.	4.6	25
8	A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma. Oncogene, 2020, 39, 6961-6974.	5.9	12
9	Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Human Gene Therapy, 2020, 31, 1132-1139.	2.7	24
10	Exploring the Roles of lncRNAs in GBM Pathophysiology and Their Therapeutic Potential. Cells, 2020, 9, 2369.	4.1	38
11	The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery, 2020, 7, 59.	1.4	5
12	Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene, 2019, 38, 6159-6171.	5.9	45
13	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. OncoImmunology, 2019, 8, e1678921.	4.6	18
14	Chromodomain Helicase DNA-Binding Protein 7 Is Suppressed in the Perinecrotic/Ischemic Microenvironment and Is a Novel Regulator of Glioblastoma Angiogenesis. Stem Cells, 2019, 37, 453-462.	3.2	20
15	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. Journal of Neuro-Oncology, 2019, 141, 289-301.	2.9	11
16	Chimeric HCMV/HSV-1 and Î”Î³134.5 oncolytic herpes simplex virus elicit immune mediated antiglioma effect and antitumor memory. Translational Oncology, 2018, 11, 86-93.	3.7	24
17	Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports, 2018, 8, 13930.	3.3	56
18	Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions. Scientific Reports, 2018, 8, 8412.	3.3	12

#	Article	IF	Citations
19	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell, 2018, 33, 1004-1016.e5.	16.8	52
20	Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Human Gene Therapy Clinical Development, 2017, 28, 7-16.	3.1	45
21	Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 449-458.	2.9	8
22	Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clinical Cancer Research, 2017, 23, 342-350.	7.0	39
23	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
24	Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Translational Oncology, 2016, 9, 419-430.	3.7	8
25	Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2016, 75, 946-954.	1.7	31
26	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy Clinical Development, 2016, 27, 69-78.	3.1	113
27	Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro-Oncology, 2016, 18, 227-235.	1.2	53
28	A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents. PLoS ONE, 2015, 10, e0145272.	2.5	9
29	ROCK Inhibition Facilitates In Vitro Expansion of Glioblastoma Stem-Like Cells. PLoS ONE, 2015, 10, e0132823.	2.5	31
30	Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. British Journal of Neurosurgery, 2015, 29, 850-858.	0.8	38
31	Dynamics of Circulating Î³Î´ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma. PLoS ONE, 2015, 10, e0122387.	2.5	17
32	Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma. PLoS ONE, 2015, 10, e0144488.	2.5	6
33	Kinomic Alterations in Atypical Meningioma. Medical Research Archives, 2015, 2015, .	0.2	6
34	Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget, 2015, 6, 4330-4344.	1.8	41
35	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors. PLoS ONE, 2014, 9, e86843.	2.5	10
36	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. Molecular Therapy, 2014, 22, 1048-1055.	8.2	233

#	Article	IF	Citations
37	Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration toAotusNonhuman Primates. Human Gene Therapy Clinical Development, 2014, 25, 16-27.	3.1	59
38	Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. Journal of Neuro-Oncology, 2014, 118, 61-72.	2.9	82
39	Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation. PLoS ONE, 2014, 9, e114110.	2.5	11
40	CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatric Blood and Cancer, 2013, 60, 45-52.	1.5	27
41	Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Neuro-Oncology, 2013, 15, 1673-1683.	1.2	20
42	Engineered Drug Resistant Î³Î´ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy. PLoS ONE, 2013, 8, e51805.	2.5	68
43	Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology, 2013, 3, 28.	2.8	11
44	Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma Multiforme. PLoS ONE, 2013, 8, e61035.	2.5	39
45	CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated VÎ´1+ Î³Î´ T Cells. PLoS ONE, 2013, 8, e68729.	2.5	39
46	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma. PLoS ONE, 2013, 8, e77753.	2.5	21
47	MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma. Clinical Cancer Research, 2012, 18, 3030-3041.	7.0	46
48	Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatric Research, 2012, 71, 500-510.	2.3	31
49	Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12. Journal of Virology, 2012, 86, 5304-5313.	3.4	68
50	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
51	Expression Signature of IFN/STAT1 Signaling Genes Predicts Poor Survival Outcome in Glioblastoma Multiforme in a Subtype-Specific Manner. PLoS ONE, 2012, 7, e29653.	2.5	118
52	Peripheral Blood Î³Î´ T Cell Response to High-Grade Glioma: Implications for Localized Adoptive Immunotherapy. Blood, 2012, 120, 4114-4114.	1.4	0
53	Downregulation of FIP200 Induces Apoptosis of Glioblastoma Cells and Microvascular Endothelial Cells by Enhancing Pyk2 Activity. PLoS ONE, 2011, 6, e19629.	2.5	22
54	Preclinical evaluation of ex vivo expanded/activated Î³Î´ T cells for immunotherapy of glioblastoma multiforme. Journal of Neuro-Oncology, 2011, 101, 179-188.	2.9	47

#	Article	IF	Citations
55	Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma. Molecular Cancer Therapeutics, 2011, 10, 2384-2393.	4.1	81
56	The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance. Molecular Cancer Research, 2011, 9, 648-659.	3.4	132
57	Cancer Stem Cells and Pediatric Solid Tumors. Cancers, 2011, 3, 298-318.	3.7	41
58	Acquisition of Chemoresistance in Gliomas Is Associated with Increased Mitochondrial Coupling and Decreased ROS Production. PLoS ONE, 2011, 6, e24665.	2.5	123
59	Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain. Journal of Biological Chemistry, 2010, 285, 39759-39767.	3.4	158
60	Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies. Molecular Therapy, 2009, 17, 1125-1135.	8.2	45
61	Characterization and immunotherapeutic potential of Î³Î´ T-cells in patients with glioblastoma. Neuro-Oncology, 2009, 11, 357-367.	1.2	69
62	Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. Journal of Neuro-Oncology, 2009, 95, 199-209.	2.9	74
63	In Reply to Dr. Speer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1274.	0.8	0
64	Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5. International Journal of Radiation Oncology Biology Physics, 2008, 71, 507-516.	0.8	29
65	CD133 Is a Marker of Bioenergetic Stress in Human Glioma. PLoS ONE, 2008, 3, e3655.	2.5	208
66	Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression. Clinical Cancer Research, 2008, 14, 4694-4704.	7.0	163
67	Tristetraprolin Down-regulates Interleukin-8 and Vascular Endothelial Growth Factor in Malignant Glioma Cells. Cancer Research, 2008, 68, 674-682.	0.9	108
68	Gene delivery into malignant glioma by infectivity-enhanced adenovirus: In vivo versus in vitro models. Neuro-Oncology, 2007, 9, 280-290.	1.2	9
69	Proteomic Identification of Biomarkers in the Cerebrospinal Fluid (CSF) of Astrocytoma Patients. Journal of Proteome Research, 2007, 6, 559-570.	3.7	67
70	Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. Journal of NeuroVirology, 2007, 13, 118-129.	2.1	12
71	A novel technique to quantify glioma tumor invasion using serial microscopy sections. Journal of Neuroscience Methods, 2006, 153, 183-189.	2.5	4
72	Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM). Journal of Neuro-Oncology, 2006, 80, 261-274.	2.9	51

#	Article	IF	Citations
73	Pharmacologic manipulations of mitochondrial membrane potential (Î”Î¨m) selectively in glioma cells. Journal of Neuro-Oncology, 2006, 81, 9-20.	2.9	10
74	Divergent effects of oncostatin M on astroglioma cells: Influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia, 2006, 53, 191-200.	4.9	22
75	Xanthine Oxidaseâ€“Dependent Regulation of Hypoxia-Inducible Factor in Cancer Cells. Cancer Research, 2006, 66, 2257-2263.	0.9	81
76	Serial Passage through Human Glioma Xenografts Selects for a Î”Î³ 1 34.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain Tumors. Journal of Virology, 2006, 80, 7308-7315.	3.4	20
77	Surface Expression of ASIC2 Inhibits the Amiloride-sensitive Current and Migration of Glioma Cells. Journal of Biological Chemistry, 2006, 281, 19220-19232.	3.4	83
78	Oncolytic HSV-1 for the treatment of brain tumours. Herpes: the Journal of the IHMF, 2006, 13, 66-71.	0.3	15
79	Polymerase Chain Reaction for the Rapid Detection of Cerebrospinal Fluid Shunt or Ventriculostomy Infections. Neurosurgery, 2005, 57, 1237-1243.	1.1	54
80	Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Therapy, 2005, 12, 359-368.	4.6	57
81	Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. Journal of Neuro-Oncology, 2005, 71, 113-119.	2.9	50
82	Glucose Metabolism Heterogeneity in Human and Mouse Malignant Glioma Cell Lines. Journal of Neuro-Oncology, 2005, 74, 123-133.	2.9	155
83	Lyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor Cells. Cancer Research, 2005, 65, 5535-5543.	0.9	97
84	Antibiotic-Mediated Chemoprotection Enhances Adaptation ofE. coliPNP for Herpes Simplex Virus-Based Glioma Therapy. Human Gene Therapy, 2005, 16, 339-347.	2.7	23
85	Inhibition of Cystine Uptake Disrupts the Growth of Primary Brain Tumors. Journal of Neuroscience, 2005, 25, 7101-7110.	3.6	281
86	Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-Oncology, 2005, 7, 213-224.	1.2	107
87	Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor Î± by Temozolomide in Experimental Glioblastoma. Cancer Research, 2004, 64, 6381-6384.	0.9	45
88	Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas. Journal of Neuro-Oncology, 2003, 65, 203-226.	2.9	113
89	Synthesis and Biological Evaluation of Paclitaxelâ€™C225 Conjugate as a Model for Targeted Drug Delivery1. Bioconjugate Chemistry, 2003, 14, 302-310.	3.6	78
90	Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells. Biochemical and Biophysical Research Communications, 2003, 309, 952-960.	2.1	15

#	Article	IF	Citations
91	Molecular cloning and characterization of human acid sensing ion channel (ASIC)2 gene promoter. Gene, 2003, 313, 91-101.	2.2	13
92	Acid-sensing Ion Channels in Malignant Gliomas. Journal of Biological Chemistry, 2003, 278, 15023-15034.	3.4	131
93	Second-Site Mutation Outside of the U _S 10-12 Domain of Î”Î³ ₁ 34.5 Herpes Simplex Virus 1 Recombinant Blocks the Shutoff of Protein Synthesis Induced by Activated Protein Kinase R and Partially Restores Neurovirulence. Journal of Virology, 2002, 76, 942-949.	3.4	31
94	Adenovirus-Mediated Transfer of BAX Driven by the Vascular Endothelial Growth Factor Promoter Induces Apoptosis in Lung Cancer Cells. Molecular Therapy, 2002, 6, 190-198.	8.2	33
95	Protein Kinase C Isoform Antagonism Controls BNaC2 (ASIC1) Function. Journal of Biological Chemistry, 2002, 277, 45734-45740.	3.4	25
96	Fas engagement increases expression of interleukin-6 in human glioma cells. Journal of Neuro-Oncology, 2002, 56, 13-19.	2.9	58
97	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Research, 2002, 62, 773-80.	0.9	91
98	Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Research, 2002, 62, 2699-707.	0.9	91
99	Human cytomegalovirus infection and expression in human malignant glioma. Cancer Research, 2002, 62, 3347-50.	0.9	518
100	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Molecular Cancer Therapeutics, 2002, 1, 1139-45.	4.1	29
101	Differential gene expression profiling in human brain tumors. Physiological Genomics, 2001, 5, 21-33.	2.3	195
102	pH Alterations â€œResetâ€•Ca2+ Sensitivity of Brain Na+ Channel 2, a Degenerin/Epithelial Na+ Ion Channel, in Planar Lipid Bilayers. Journal of Biological Chemistry, 2001, 276, 38755-38761.	3.4	23
103	Genetically engineered HSV in the treatment of glioma: a review. , 2000, 10, 17-30.		74
104	Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy, 2000, 7, 867-874.	4.5	914
105	Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. Journal of Neuro-Oncology, 2000, 46, 135-144.	2.9	75
106	<title>Implications of laser light characteristics on the Raman signal-to-noise ratio in diagnostic analysis of glioblastoma multiforme</title>. , 1998, 3250, 2.		0
107	<title>Raman spectroscopy for in situ- evaluation of high-grade malignant gliomas induced in SCID mice</title>. , 1997, , .		1
108	In VivoGene Therapy of Cancer withE. coliPurine Nucleoside Phosphorylase. Human Gene Therapy, 1997, 8, 1637-1644.	2.7	110

#	Article	IF	Citations
109	In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nature Biotechnology, 1997, 15, 462-466.	17.5	109
110	Immunoreactivity of human MAb BT32/A6 with neuroepithelial tumors. Journal of Neuro-Oncology, 1997, 35, 93-100.	2.9	0
111	Brain Edema in Meningiomas Is Associated with Increased Vascular Endothelial Growth Factor Expression. Neurosurgery, 1997, 40, 1269-1277.	1.1	156
112	Human astrocytoma cells express a unique chloride current. NeuroReport, 1996, 7, 1020-1024.	1.2	48
113	Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. Journal of Neurosurgery, 1995, 82, 864-873.	1.6	239
114	Human astrocytoma cells express a unique chloride current. NeuroReport, 1995, 7, 343-347.	1.2	0
115	Production of a Bioactive High Molecular Weight Transforming Growth Factor Beta-Like Molecule by Human Malignant Glioma Cell Lines. Growth Factors, 1994, 11, 153-162.	1.7	4
116	Partial characterization of glioma-derived growth factor 2: A novel mitogenic activity from human cell line D-54 MG. Journal of Neuro-Oncology, 1993, 17, 99-109.	2.9	2
117	Interleukin-1Î² induction of tumor necrosis factor-alpha gene expression in human astroglioma cells. Journal of Neuroimmunology, 1992, 36, 179-191.	2.3	73
118	Interleukin-1? induction of TNF-? gene expression: Involvement of protein kinase C. Journal of Cellular Physiology, 1992, 152, 264-273.	4.1	57
119	Computerized tomography brain scan tumor volume determinations. Journal of Neurosurgery, 1990, 72, 872-878.	1.6	20
120	Tumor necrosis factor production and receptor expression by a human malignant glioma cell line, D54-MG. Journal of Neuroimmunology, 1990, 30, 1-13.	2.3	60
121	Systemic beta-interferon therapy for recurrent gliomas: a brief report. Journal of Neurosurgery, 1989, 71, 639-641.	1.6	20
122	Growth factors derived from a human malignant glioma cell line, U-251MG. Journal of Neuro-Oncology, 1989, 7, 225-235.	2.9	16
123	A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats. Journal of Neurosurgery, 1989, 71, 898-902.	1.6	1
124	Intracarotid cisplatin chemotherapy for recurrent gliomas. Journal of Neurosurgery, 1989, 70, 371-378.	1.6	89
125	Systemic gamma-interferon therapy for recurrent gliomas. Journal of Neurosurgery, 1988, 69, 826-829.	1.6	50
126	[19] Derivation of monoclonal antibodies to human somatomedin C/insulin-like growth factor I. Methods in Enzymology, 1987, 146, 207-216.	1.0	10

#	Article	IF	Citations
127	Treatment of autochthonous rat brain tumors with steroid plus heparin: A brief report. Journal of Neuro-Oncology, 1987, 5, 161-162.	2.9	2
128	Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. Cancer, 1987, 59, 266-270.	4.1	50
129	Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro. Journal of Neurosurgery, 1986, 64, 918-923.	1.6	44
130	Macrophage-Derived Growth Factor for Fibroblasts and Interleukin-1 Are Distinct Entities. Journal of Leukocyte Biology, 1984, 35, 115-129.	3.3	68
131	Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 2347-2351.	7.1	56
132	Immunobiology of primary intracranial tumors. Journal of Neurosurgery, 1983, 59, 208-216.	1.6	25
133	Mitogenic activity elaborated by macrophage-like cell lines acts as competence factor(s) for BALB/c 3T3 cells. Journal of Cellular Physiology, 1982, 110, 93-100.	4.1	54
134	Development and persistence of cytolytic T lymphocytes in regressing or progressing moloney sarcomas. International Journal of Cancer, 1978, 21, 94-99.	5.1	16
135	B-tropic oncornavirus production by BALB/c methylcholanthrene-induced sarcoma cells. International Journal of Cancer, 1978, 21, 234-238.	5.1	5
136	Lymphocyte mediated reactivity against malignant melanoma detected by a microcytotoxicity assay employing technetium-99m labeled target cells. Cancer, 1978, 41, 2174-2182.	4.1	2
137	Isolation of T-Lymphocytes From Disaggregated Tumors, With High Purity and Good Percentage Recovery: Brief Communication23. Journal of the National Cancer Institute, 1977, 59, 273-275.	6.3	8
138	Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of moloney sarcoma regression or progression. International Journal of Cancer, 1976, 18, 331-338.	5.1	54
139	Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomas. International Journal of Cancer, 1975, 16, 1022-1029.	5.1	120